▲ +48.69% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $17.86, with a high forecast of $23.00 and a low forecast of $11.00. The average price target represents a 48.69% upside from the last price of $12.01.
The current consensus among 8 contributing investment analysts is to buy stock in Fulcrum Therapeutics. This rating has held steady since October 2020, when it changed from a Hold consensus rating.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.